Drug Profile
Research programme: influenza monoclonal antibody therapeutics - ContraFect/Trellis
Alternative Names: Anti-H1 mAb - ContraFect; Anti-H3 mAb - ContraFect; Anti-Influenza mAb combination - ContraFect; CF 401; CF 402; CF 403; CF 404Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Trellis Bioscience
- Developer ContraFect; Trellis Bioscience
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in USA (Intranasal)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Influenza-B-virus-infections in USA (Intranasal)
- 01 May 2019 ContraFect enters into an option agreement with Trellis Bioscience for reverting rights to the CF 404 programme